Apnimed (Nasdaq: APMD) granted options to purchase 331,000 common shares to new non-executive employees on November 2, 2026. The awards cover 14 employees and have an exercise price of $15.40 per share, equal to the closing trading price on the grant date.
One fourth of each employee’s options vest on the first anniversary of their start date, with equal monthly installments over the next three years, subject to continued employment. The awards were employment inducements under the 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The board adopted the plan on August 21, 2026.
Apnimed (Nasdaq: APMD) will present five accepted abstracts at CHEST 2026, taking place October 18–21 in Phoenix, Arizona.
Three abstracts cover the Phase 3 program for AD109, an investigational drug for obstructive sleep apnea (OSA), including two late-breaking presentations. Topics include post-menopausal women, oxygen deprivation during sleep as a potential marker of blood pressure response, and patient-reported outcomes. Two other abstracts address real-world OSA burden. A CHEST panel on October 20 will discuss the SynAIRgy and LunAIRo trial results and their potential application to OSA management.
Apnimed (APMD) granted stock options covering 481,300 shares to new non-executive employees on October 1, 2026, as employment inducements.
The awards went to 19 employees under the 2026 Inducement Plan. Each option has an exercise price of $22.54 per share, equal to the closing trading price on the grant date. One-fourth vests on the first anniversary of each employee’s start date, with equal monthly installments over the next three years, subject to continued employment. The compensation committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Apnimed (APMD) reported second quarter 2026 results and major corporate milestones tied to its OSA candidate AD109 (proposed name Oxnimbi).
The FDA accepted the NDA for Oxnimbi for adults with obstructive sleep apnea and assigned a PDUFA target action date of February 28, 2027. Oxnimbi has completed two Phase 3 trials (SynAIRgy and LunAIRo), and Apnimed is advancing commercial readiness for a potential U.S. launch if approved. During the quarter the company expanded its leadership team, completed an upsized IPO of 13.8 million shares at $16.00 for $220.8 million in gross proceeds, and secured a senior secured credit facility of up to $150 million.
Apnimed also monetized its interest in Shionogi-Apnimed Sleep Science for $100 million upfront plus potential milestones and royalties, ended June 30, 2026 with $172.8 million in cash and equivalents, and turned to net income of $125.9 million versus a $69.5 million net loss a year earlier, driven largely by a $85.4 million gain on sale of an equity method investment and a $57.1 million gain on reversal of a deposit liability. Common stock began trading on the Nasdaq Global Select Market on July 31, 2026 under ticker APMD.
Apnimed (APMD) reported that on August 31, 2026 its compensation committee granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of common stock under the 2026 Inducement Plan.
Each option has an exercise price of $26.85 per share, equal to Apnimed’s closing trading price on September 1, 2026. One-fourth of the shares underlying each grant vest on the first anniversary of the employee’s start date, with the remainder vesting in equal monthly installments over the following three years, subject to continued employment. The awards were approved as inducement grants under Nasdaq Listing Rule 5635(c)(4), and the Plan was adopted by the board on August 21, 2026.
Apnimed (Nasdaq: APMD) closed its upsized initial public offering of an aggregate 13,800,000 shares of common stock at an initial public offering price of $16.00 per share, including 1,800,000 additional shares from the underwriters’ fully exercised overallotment option. All shares were sold by Apnimed, generating gross proceeds of $220.8 million before underwriting discounts, commissions and offering expenses. Apnimed’s stock began trading on the Nasdaq Global Select Market under the ticker “APMD” on July 31, 2026. BofA Securities, Evercore ISI, Cantor and LifeSci Capital served as joint book-running managers.
Apnimed (Nasdaq: APMD) priced its upsized initial public offering of 12,000,000 common shares at $16.00 per share, implying expected gross proceeds of $192 million before fees and expenses. The company also granted underwriters a 30-day option to purchase up to 1,800,000 additional shares at the IPO price, less discounts and commissions.
Apnimed common stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026 under the ticker “APMD”, with closing anticipated on or about August 3, 2026, subject to customary conditions. All shares are being sold by Apnimed, with BofA Securities, Evercore ISI, Cantor and LifeSci Capital as joint book-running managers.